(1)
VANCOUVER, BC / ACCESSWIRE / April 5, 2021 /
Commerce Resources Corp. (TSXV:CCE)(FSE:D7H0)(OTCQX:CMRZF) (the Company or Commerce ) is pleased to provide an update on the progress of the Prefeasibility Study (PFS) for the Ashram Rare Earth and Fluorspar Deposit. The Company is pleased to announce that it has engaged several specialized engineering firms to advance the remaining key components of the PFS through to completion.
The Company has retained DRA Americas Inc. and L3 Process Development for review and assessment of the Ashram Deposit s flowsheet. The selection maintains the direct involvement of several key metallurgical Qualified Persons (QPs) who have a strong familiarity with the specifics of the flowsheet through past work programs.
- Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03
- Global Phase 1/2 trial – GALax-C – PBKR03 planned to initiate in first half of 2021
PHILADELPHIA, April 05, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often presents early in a child’s life. The U.S. Food and Drug Administration (FDA)
Covid 19 coronavirus: Melbourne man s blood clot condition likely linked to vaccine, but rollout to continue
3 Apr, 2021 06:04 AM
2 minutes to read
Pharmacist Mario Linaksita, right, administers the AstraZeneca Covid-19 vaccine to Sharon Berringer, 56, at University Pharmacy, in Vancouver, British Columbia. Photo / AP
Pharmacist Mario Linaksita, right, administers the AstraZeneca Covid-19 vaccine to Sharon Berringer, 56, at University Pharmacy, in Vancouver, British Columbia. Photo / AP
news.com.au
By: Anton Nilsson
Australian health officials will continue to administer AstraZeneca coronavirus vaccinations after a Melbourne man who had received the jab fell ill with a rare blood clotting condition.
The Friday hospitalisation prompted an urgent meeting of independent experts on Saturday morning.
Covid 19 coronavirus: Warning after man in Victoria, Australia, develops blood clots following vaccine
2 Apr, 2021 06:43 AM
4 minutes to read
The World Health Organisation and the EU s health watchdog have both deemed the AstraZeneca vaccine, pictured, safe after fears were raised of the jab having serious side effects. Photo / AP
The World Health Organisation and the EU s health watchdog have both deemed the AstraZeneca vaccine, pictured, safe after fears were raised of the jab having serious side effects. Photo / AP
news.com.au
A Victorian man has been admitted to hospital with a rare blood clotting disorder just a few days after receiving the AstraZeneca vaccine.